Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes.

Autor: Vennegoor CJ; Department of Obstetrics and Gynecology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands. c.vennegoor@azvu.nl, Nijman HW, Drijfhout JW, Vernie L, Verstraeten RA, von Mensdorff-Pouilly S, Hilgers J, Verheijen RH, Kast WM, Melief CJ, Kenemans P
Jazyk: angličtina
Zdroj: Cancer letters [Cancer Lett] 1997 Jun 03; Vol. 116 (1), pp. 93-101.
DOI: 10.1016/s0304-3835(97)00168-7
Abstrakt: Autoantibodies against complete p53 protein and 18-mer peptides of p53 in ovarian cancer patients and healthy women were examined. Sera from 9% (4/46) of ovarian cancer patients but none (0/51) of healthy women recognized complete p53 protein. The antibodies were mainly of the IgG1 isotype. Two patients had also IgG2 antibodies. Sera from 28% (13/46) of cancer patients and 21% (11/52) of healthy women contained either IgM, or IgM plus IgG2 antibodies against 18-mer p53 peptides. Screening against complete p53 protein instead of peptides seems necessary for identifying patients with tumor-related antibodies. IgG2 antibodies against p53 suggest p53-specific CD4+ T helper 1 cell activity in some of the ovarian cancer patients.
Databáze: MEDLINE
Externí odkaz: